AMARIN CORP PLC\UK Increase (Decrease) in Accrued Interest Receivable, Net
AMARIN CORP PLC\UK (AMRN) reported Increase (Decrease) in Accrued Interest Receivable, Net of -$120.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-07-29
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for the quarter ending 2026-06-30 was -$157.00K, a 623.33% decline year-over-year.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for the quarter ending 2026-03-31 was $37.00K.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for the quarter ending 2025-12-31 was -$279.00K.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for the quarter ending 2025-09-30 was -$29.00K, a 111.65% decline year-over-year.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for fiscal 2025 was -$728.00K, a 1140.00% decline from fiscal 2024.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for fiscal 2024 was $70.00K.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for fiscal 2023 was -$248.00K.
- AMARIN CORP PLC\UK increase (decrease) in accrued interest receivable, net for fiscal 2022 was -$341.00K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 3 month as first filed | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$120.00K 10-Q · filed 2026-07-29 | -$399.00K derived: sum of 3 quarters · filed 2026-07-29 | -$428.00K derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $37.00K 10-Q · filed 2026-04-29 | -$242.00K derived: sum of 2 quarters · filed 2026-04-29 | -$271.00K derived: sum of 3 quarters · filed 2026-04-29 | -$241.00K derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | -$279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$308.00K derived: sum of 2 quarters · filed 2026-03-02 | -$278.00K derived: sum of 3 quarters · filed 2026-07-29 | -$728.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | -$29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.00K derived: sum of 2 quarters · filed 2026-07-29 | -$449.00K 10-Q · filed 2025-10-29 | -$629.00K derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | $30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$420.00K 10-Q · filed 2026-07-29 | -$600.00K derived: sum of 3 quarters · filed 2026-07-29 | -$351.00K derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | -$450.00K 10-Q · filed 2026-04-29 | -$630.00K derived: sum of 2 quarters · filed 2026-04-29 | -$381.00K derived: sum of 3 quarters · filed 2026-04-29 | -$380.00K derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | -$180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $69.00K derived: sum of 2 quarters · filed 2026-03-02 | $70.00K derived: sum of 3 quarters · filed 2026-03-02 | $70.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $250.00K derived: sum of 2 quarters · filed 2025-10-29 | $250.00K 10-Q · filed 2025-10-29 | $206.00K derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $1.00K 10-Q · filed 2025-07-30 | -$43.00K derived: sum of 3 quarters · filed 2026-03-02 | -$143.00K derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 | -$44.00K derived: sum of 2 quarters · filed 2026-03-02 | -$144.00K derived: sum of 3 quarters · filed 2026-03-02 | -$232.00K derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$144.00K derived: sum of 2 quarters · filed 2026-03-02 | -$232.00K derived: sum of 3 quarters · filed 2026-03-02 | -$248.00K 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$188.00K derived: sum of 2 quarters · filed 2024-10-30 | -$204.00K 10-Q · filed 2024-10-30 | -$62.00K derived: sum of 4 quarters · filed 2025-03-12 | |
| 2023-06-30 | -$88.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | -$104.00K 10-Q · filed 2024-07-31 | $38.00K derived: sum of 3 quarters · filed 2025-03-12 | -$216.00K derived: sum of 4 quarters · filed 2025-03-12 | |
| 2023-03-31 | -$16.00K 10-Q · filed 2024-05-01 | $16.00K 10-Q · filed 2023-05-03 | $126.00K derived: sum of 2 quarters · filed 2025-03-12 | -$128.00K derived: sum of 3 quarters · filed 2025-03-12 | -$217.00K derived: sum of 4 quarters · filed 2025-03-12 |
| 2022-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$112.00K derived: sum of 2 quarters · filed 2025-03-12 | -$201.00K derived: sum of 3 quarters · filed 2025-03-12 | -$341.00K 10-K · filed 2025-03-12 | |
| 2022-09-30 | -$254.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$343.00K derived: sum of 2 quarters · filed 2023-11-01 | -$483.00K 10-Q · filed 2023-11-01 | -$498.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-06-30 | -$89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$229.00K 10-Q · filed 2023-08-02 | -$244.00K derived: sum of 3 quarters · filed 2024-02-29 | -$295.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2022-03-31 | -$140.00K 10-Q · filed 2023-05-03 | -$155.00K derived: sum of 2 quarters · filed 2024-02-29 | -$206.00K derived: sum of 3 quarters · filed 2024-02-29 | -$760.00K derived: sum of 4 quarters · filed 2024-02-29 | |
| 2021-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$66.00K derived: sum of 2 quarters · filed 2024-02-29 | -$620.00K derived: sum of 3 quarters · filed 2024-02-29 | -$738.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | -$605.00K derived: sum of 2 quarters · filed 2022-10-27 | -$723.00K 10-Q · filed 2022-10-27 | -$1.13M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$554.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$672.00K 10-Q · filed 2022-08-03 | -$1.07M derived: sum of 3 quarters · filed 2023-03-01 | -$655.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | -$118.00K 10-Q · filed 2022-05-04 | -$521.00K derived: sum of 2 quarters · filed 2023-03-01 | -$101.00K derived: sum of 3 quarters · filed 2023-03-01 | $190.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$403.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $17.00K derived: sum of 2 quarters · filed 2023-03-01 | $308.00K derived: sum of 3 quarters · filed 2023-03-01 | $1.33M 10-K · filed 2023-03-01 | |
| 2020-09-30 | $420.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $711.00K derived: sum of 2 quarters · filed 2021-11-03 | $1.73M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $291.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.31M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $1.02M 10-Q · filed 2021-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |